Loading...
Market
What will be the outcome of the phase 1 trials for Johnson & Johnson's TSLP targeting asset within 18 months of acquiring Proteologix?
4
Resolution / Starting Odds
Successful • 33%
Partially successful • 34%
Unsuccessful • 33%
clinical trial results and FDA updates
Story
Johnson & Johnson to Acquire Proteologix for $850 Million, Including Dual-Targeting Antibody Drugs
May 16, 2024, 12:25 PM
Johnson & Johnson announced on Thursday that it will acquire privately held Proteologix for $850 million in cash, with potential for an additional milestone payment. The acquisition aims to bolster Johnson & Johnson's leadership in the treatment of atopic dermatitis. Proteologix brings a young roster of bispecific immunology medications, including a phase 1-ready asset targeting TSLP and dual-targeting antibody drugs. The acquisition has seen Johnson & Johnson's stock (JNJ) rise by 0.1% in pre-market trading.
View original story
Similar markets
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Standalone Unit • 25%
Merged with J&J Immunology Division • 25%
Merged with J&J Research and Development • 25%
Dissolved with Assets Redistributed • 25%
Positive results • 33%
Neutral results • 34%
Negative results • 33%
Successful • 33%
Mixed results • 34%
Unsuccessful • 33%
Significant increase in revenue • 25%
Moderate increase in revenue • 25%
No significant impact on revenue • 25%
Decrease in revenue • 25%
Significant increase in J&J stock price • 33%
Moderate increase in J&J stock price • 34%
No significant change in J&J stock price • 33%
Success • 33%
Partial Success • 33%
Failure • 33%
Does not progress past Phase 1 • 25%
Completes Phase 1 but not Phase 2 • 25%
Completes Phase 2 but not Phase 3 • 25%
Advances to Phase 3 or beyond • 25%
